Neopharma Technologies Limited  announced a global software licensing and collaboration agreement with Zhejiang Orient Gene Biotech Co., Ltd. ("Orient Gene") to integrate Neopharma's NEOVAULT® digital platform across Orient Gene’s range of Drugs of Abuse (DOA) rapid tests, marketed under the Healgen® brand.

This collaboration merges Neopharma’s secure, cloud-based NEOVAULT® software with Healgen®'s proven rapid testing technology, delivering a fully digital, end-to-end drug testing solution. Key benefits include tamper-evident result capture at the point of testing, automated audit trails for safety-critical environments, and instant, de-identified analytics to identify usage trends by location, time, and risk factors—enabling earlier and more targeted interventions.

The NEOVAULT® platform is designed for seamless integration with existing HR and clinical systems, streamlining compliance and reporting workflows while enhancing organizational readiness and responsiveness.

This partnership directly supports priorities outlined by the White House Office of National Drug Control Policy (ONDCP) in its April 1, 2025 statement. Specifically, it addresses:

• Priority 1 — Reducing Overdose Fatalities: NEOVAULT® digitizes rapid test results and can flag fentanyl positives in real time, creating dynamic heat maps to assist U.S. authorities in overdose prevention efforts.

• Priority 6 — Innovation in Research and Data: The system produces accurate, shareable data for advanced analytics, supporting AI/ML-driven decision-making and public-private collaboration to modernize drug testing and combat emerging substance abuse threats.

NEOVAULT® meets global standards for security and privacy, including ISO 27001 certification, SOC 2 Type II attestation, HIPAA compliance, and GDPR-aligned controls—ensuring safe and lawful data handling across jurisdictions.

Executive Perspectives

Marcus L'Estrange, Executive Chairman of Neopharma Technologies, said:
“We are raising the global standard for digital drug testing. By enabling Healgen®'s extensive DOA portfolio with NEOVAULT®, we transform paper-based results into structured intelligence—helping employers act faster and giving policymakers real-time insights.”

Byran Fang, President of Orient Gene, added:
“As a global leader in In-Vitro Diagnostics, Orient Gene is committed to advancing both the accuracy and accessibility of rapid testing. This partnership ensures our customers benefit from the trusted performance of Healgen® devices and the added value of secure, real-time digital reporting.”

What Customers Can Expect

• NEOVAULT®-enabled Healgen® devices: Maintain the same user-friendly testing workflow, now enhanced with guided digital capture, scannable kit IDs, and instant result transmission.

• NEOVAULT® ERM Platform: A secure, mobile-friendly tool for Third Party Administrators and drug testing providers to generate and manage digital reports in the field. HR teams gain real-time hiring decision support, cutting result wait times from days to minutes.

• Enterprise Integration: API connectors to major HRIS platforms with role-based access control, ensuring secure and scalable adoption across industries.

Together, Neopharma and Orient Gene are delivering the next generation of drug testing—faster, smarter, and ready for the future.